Epidemiological characteristics and precise prophylaxis and control of HBV-associated primary liver cancer

Hepatoma Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 18, 2025

Primary liver cancer (PLC), which includes hepatocellular carcinoma (HCC, 93% in China; 75%-80% worldwide), intrahepatic cholangiocarcinoma (ICC, 4.3% 10%-15% and combined (CHC, 1.6% China), is a global disease that brings heavy burden to the world number of incidence cases on rise. Chronic injury caused by factors such as exposure aflatoxin B1, infection with Clonorchis sinensis, alcohol consumption, chronic hepatitis C virus (HCV), metabolic syndrome are all known risk for PLC. Notably, B (HBV) major factor HCC. Globally, PLC changing from infectious causes factors. Here, we update mechanisms HBV-related HCC (HBV-HCC) development, especially effect HBV evolution development The mutations, viral load, integration, together parameters poor function, key components define highest-risk population HBV-HCC. Antiviral therapy has been proven be effective prevention HBV-HCC population. Non-invasive imaging markers economical convenient screening early Surgical resection transplantation therapeutic options HCC; however, postoperative recurrence reaches 70% five years. Targeted therapy, immunotherapy, radiotherapy can improve survival Active prophylaxes, including vaccination, antiviral treatment, improving lifestyle decrease inflammation, surveillance, cost-effective decreasing

Language: Английский

Metabolism, sex, and what lies beyond the scalpel in MASLD

Metabolism and Target Organ Damage, Journal Year: 2025, Volume and Issue: 5(2)

Published: April 2, 2025

The discovery of the one-carbon metabolism-homocysteine-metabolic dysfunction-associated steatotic liver disease (OCM-Hcy-MASLD) axis has renewed our understanding MASLD-related primary cancer (PLC). Based on Suzuki et al.’s mathematical modeling findings diminished cystathionine β-synthase (CBS) and phosphatidylethanolamine N-methyltransferase (PEMT) expression in MASLD, this commentary analyzes recent regarding sex-specific variations their implications for surgical management. We highlight how integration OCM-Hcy pathway modulation with precise interventions could enhance perioperative outcomes long-term prognosis. emerging evidence suggests that targeted metabolic interventions, particularly those accounting sex differences, may complement traditional approaches by addressing systemic nature PLC. This paradigm shift from purely resection toward comprehensive regulation marks a significant advance precision medicine hepatobiliary surgery, potentially improving both safety oncological outcomes.

Language: Английский